Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MIRA Pharmaceuticals, Inc. ( (MIRA) ) has provided an update.
MIRA Pharmaceuticals has initiated the multiple ascending dose (MAD) phase of its Phase 1 clinical trial for Ketamir-2, targeting chemotherapy-induced peripheral neuropathy (CIPN) as the lead indication for Phase 2a evaluation. This development is significant as there are currently no FDA-approved treatments for CIPN, and Ketamir-2 has shown promising preclinical results, potentially positioning it as a non-opioid therapy that could qualify for FDA Fast Track designation.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing novel therapies for conditions with significant unmet medical needs. The company’s primary product is Ketamir-2, an oral analog of ketamine designed to treat neuropathic pain without the limitations of traditional ketamine use.
Average Trading Volume: 3,101,092
Technical Sentiment Signal: Buy
Current Market Cap: $27.65M
Learn more about MIRA stock on TipRanks’ Stock Analysis page.